ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

ClinicalTrials.gov ID: NCT03267680

Public ClinicalTrials.gov record NCT03267680. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two-Cohort, Open-label Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

Study identification

NCT ID
NCT03267680
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Southern California
Other
Enrollment
10 participants

Conditions and interventions

Interventions

  • Cyclophosphamide Drug
  • IRX-2 Biological
  • Indomethacin Drug
  • Laboratory Biomarker Analysis Other
  • Multivitamin Dietary Supplement
  • Omeprazole Drug
  • Placebo Other
  • Therapeutic Conventional Surgery Procedure

Drug · Biological · Other + 2 more

Eligibility (public fields only)

Age range
25 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 7, 2017
Primary completion
Aug 3, 2023
Completion
Mar 12, 2024
Last update posted
Apr 12, 2025

2017 – 2024

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
USC / Norris Comprehensive Cancer Center Los Angeles California 90033
University of Oklahoma Health Sciences Center, Stephenson Cancer Center Oklahoma City Oklahoma 73104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03267680, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03267680 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →